An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients

Trial Profile

An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Folitixorin (Primary) ; Folinic acid; Methotrexate
  • Indications Folic acid deficiency; Osteosarcoma
  • Focus Adverse reactions
  • Sponsors Isofol Medical
  • Most Recent Events

    • 18 May 2017 This trial has been completed in Sweden (end date: 3 Jan 2017).
    • 01 Apr 2017 This trial has been completed in Czech Republic (2017-01-03), according to European Clinical Trials Database.
    • 29 Mar 2017 This trial has been completed in Hungary (End date:2017-01-03) as per European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top